Israeli artificial intelligence (AI) solutions company RSIP Vision has partnered with BioView, a cell imaging and analysis solutions provider, to use artificial intelligence (AI) for classifying chromosomes for accurate genetic testing.
Chromosome classification for genetic testing, known as karyotype classification, involves pairing of chromosomes to identify any irregularities.
The procedure is often performed manually by cytologists. However, the manual approach is expensive and time-consuming.
The AI solution is expected to reduce time, as well as the expense associated with genetic testing, providing a significant improvement in results.
RSIP Vision CEO Ron Soferman said: “Machine learning provides the unique capability to both segment and straighten out chromosomes so that the results that the patient receives are as accurate as possible.
“When patients are undergoing genetic testing, it is often a sensitive time for them – they are testing for various conditions that could potentially affect their lives forever. Reducing the time for patients to receive the results of genetic testing is a step in making this process easier and smoother, providing patients with the correct answers, faster.”
During karyotype classification, cytologists analyse chromosome size, shape and number, as well as abnormal locations and pieces. The information indicates abnormal growth development or body functioning.
Machine learning boosts the genetic testing process through the capture of several data sets for the training phase.
RSIP Vision and BioView leveraged a deep learning technique trained on extensive datasets to facilitate precise data correlations for fast identification of any abnormalities.
BioView deployed the AI solution in Duet Image and Analysis systems at hospitals across the US and Europe. The solution led to increased testing throughput, as well as more accurate results when compared to other solutions, according to the company’s customers.